ATX

AMPLIA FPO [ATX]
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.1400 +0.0%

Updated 22 Jul 2026 · Signals refresh every scan

Get alerts when ATX triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track ATX — Free

Active Signals

Bullish Signals

  • Stochastic is deep in oversold territory — bounce conditions forming
  • Bollinger Bands are tightening — volatility is coiling up for a potential breakout
  • Trading above both moving averages — the trend is your friend here
  • Beating the Small Ords index — relative strength of 1.18, so it's outpacing the pack
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Trading above the 200-day average — the long-term trend is on your side
  • Strong cash runway (13 quarters)
  • Moderate P/S ratio (15.0x)
  • EPS estimates revised upward (+10pts)
  • Small-cap ($20-100M)
  • CANSLIM I: Institutional ownership (23%)
  • Sentiment is mixed — no strong consensus either way
  • The bigger volume days are the up days — volume-weighted momentum is positive (1.11%/day)
  • RBA hiking (-3pts)

Risk Signals

  • Revenue declining (-9%)
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-161%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 22% over the past year
Ask Scout AI about ATX
"What's driving ATX today?" "How does ATX compare to peers?" "Key risks for ATX?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Notification regarding unquoted securities - ATX
NONE Notification regarding unquoted securities - ATX
NONE Amplia Therapeutics Shareholder Webinar

Recent ASX Announcements

2026-07-15 Notification regarding unquoted securities - ATX
2026-07-15 Notification regarding unquoted securities - ATX
2026-07-12 Amplia Therapeutics Shareholder Webinar
2026-07-06 Initial Director's Interest Notice - Brett Carter
2026-07-05 Amplia Announces Appointment of Brett Carter to Board

Key Metrics

$71.9M
Market Cap
1.1M
Avg Volume
0.4x
Vol Ratio
$0.10 — $0.28
52-Week Range
0.0%
Short Interest
N/A
Cash Runway
-25.5%
ROE
-160.9%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 81%
LLeader vs LaggardlaggardRS: -8
IInstitutional SponsorshippassInst: 23%
MMarket DirectionneutralNeutral

Sector: Healthcare

101 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
IDT +28.1%ADR +27.3%LDX +23.8%EYE +17.4%ECS -16.7%
Compare:ATX vs IDTATX vs ADRATX vs LDX
Scout Pro — Deeper Analysis for ATX
Try Pro free for 30 days
Share this analysis

Track ATX and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required